{"id":"W4394008906","doi":"10.1016/j.eururo.2024.03.015","title":"Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study","year":2024,"lang":"en","type":"article","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University of Alberta; McMaster University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Western University","funders":"National Cancer Institute; Genentech; European Society for Medical Oncology; Astellas Pharma; National Comprehensive Cancer Network; Eisai; Ipsen; BeiGene; Daiichi Sankyo Europe; Exelixis; Memorial Sloan-Kettering Cancer Center; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lenvatinib; Internal medicine; Confidence interval; Renal cell carcinoma; Pembrolizumab; Sunitinib; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Oncology; Phases of clinical research; Urology; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004602021,0.0003283018,0.001191749,0.0007308947,0.0002480307,0.0005293216,0.0003643031,0.0004289391,0.0004996074],"category_scores_gemma":[0.00333738,0.0001456428,0.001061373,0.0006539224,0.0001942439,0.0004061621,0.000363826,0.000745663,0.0001773454],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004392551,"about_ca_system_score_gemma":0.0003470051,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005657233,"about_ca_topic_score_gemma":0.001119498,"domain_scores_codex":[0.9980891,0.0008918874,0.0002248302,0.0002954925,0.0003507592,0.0001478074],"domain_scores_gemma":[0.9967764,0.001269848,0.001115229,0.0002121384,0.0002805924,0.0003459062],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.02744908,0.0003609634,0.9304183,0.0002112292,0.001395237,0.000223638,0.0001888388,0.001850637,0.007874845,0.00005048773,0.0005436385,0.02943314],"study_design_scores_gemma":[0.0003967999,0.004385666,0.9917436,0.00001056247,0.000284516,0.000265654,0.00004754182,0.001105445,0.0009637609,0.00004472897,0.0007392552,0.00001241392],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966455,0.001512677,0.0003145889,0.00005095213,0.000006576605,0.00008889312,0.0008182313,0.00001360471,0.0005488569],"genre_scores_gemma":[0.9979801,0.0001362194,0.0001386248,0.00006389921,0.00001228285,0.00005728856,0.001470097,0.000003871304,0.0001377245],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004602021,"threshold_uncertainty_score":0.02433807,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02779521509965852,"score_gpt":0.2702784539642715,"score_spread":0.242483238864613,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}